Opsona Therapeutics is a leading drug development company specialising in the human immune system.

Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.

Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline of drugs. The company has research locations in Dublin (Ireland) and Lausanne (Switzerland). Find out more about Opsona

Our Products
Opsona Therapeutics is developing a number of highly innovative products to modulate the human immune system.

Our ability to deliver is reflected in our partnerships with global companies such as Wyeth and investors including Genentech & Novartis Venture Funds.

Discover more about Opsona’s products.

Innate immune system and adaptive immune system

Our Research

Our research is focused on using targeted approaches to explore the role of Toll-Like Receptors in innate immune pathways.

A large body of recent scientific research suggests that understanding TLRs & TLR signalling is the key to developing improved drugs for the treatment of autoimmune/inflammatory conditions, cancers and infectious diseases.

latest news

ROCHE VENTURE FUND, ENTERPRISE IRELAND COMMIT €3.3 M TO OPSONA SERIES B FINANCING
ROCHE VENTURE FUND, ENTERPRISE IRELAND COMMIT €3.3 M TO OPSONA SERIES B FINANCING -Completed Series B Total Stands At €21.3 m

OPSONA & LONZA enter into manufacturing agreement for the production of a monoclonal antibody OPN-305 developed by OPSONA Therapeutics Ltd.
Read More on OPSONA Therapeutics & LONZA manufacturing agreement

OPSONA, CSL Form Vaccine Adjuvant R&D Collaboration Targeting Infectious Diseases And Oncology
Opsona announce that it has signed a research and collaboration agreement with the global specialty biopharmaceutical company CSL Limited. The collaboration covers the identification of novel vaccine adjuvant formulations, based on Opsona's proprietary technology OpsoVacTM which could target infectious diseases and certain cancers.